EAST END GROUP, LLC

Lobbying for ALVOGEN · Pharmaceutical company developing and manufacturing generic, brand and biosimilar products

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $45,000.00 income · posted Oct 17, 2025

Lobbying activity 3

Health Issues

Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals.

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

Manufacturing

Buy America legislation, 232 tariff investigation, regulatory incentives for domestic manufacturing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.